Clinical and molecular landscape of metastatic extramammary Paget’s disease
The Oncologist · 01.09.2025 · 30 (9)
DOI: 10.1093/oncolo/oyaf235 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 28.07.2025. Verfasst von Satomi Watanabe und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan. Hauptthemen laut MEDLINE: Paget Disease, Extramammary. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI.
Abstract (Originalsprache)
Background
Extramammary Paget’s disease (EMPD) is a rare malignancy without established systemic therapy. EMPD shares molecular features with breast cancer, such as human epidermal growth factor receptor 2 (HER2) and hormone receptor (HR) expression, but their clinical relevance remains unclear. Materials and Methods Tumors from 20 metastatic invasive EMPD cases were analyzed for molecular and biological features. Genomic features, transcriptomic profiles, and HER2 and HR expression status were investigated using immunohistochemistry, fluorescence in situ hybridization, and targeted-genome next-generation sequencing and nCounter BC360 panels. Metastatic breast cancer samples were used as a comparison to clarify metastatic EMPD’s clinical relevance.
Results
Estrogen receptor expression was observed in 45% of EMPD tumors, while only 10% expressed progesterone receptor. HER2 was overexpressed in 30% of cases, and HER2-directed therapies were durably effective. Among 8 patients with NGS data, 63% (5/8) harbored oncogenic ERBB2 alterations independent of HER2 expression. BC360 profiling revealed biological differences between EMPD and breast cancer, particularly poor biological compatibility for HR-positive tumors. Immune profiling showed that a subset of EMPD tumors exhibited CD8+ T-cell signatures and PD-1/PD-L1 gene expression comparable to triple-negative breast cancer. The median overall survival was 22.1 months (95% CI, 12.0-42.2), with 16 patients (80%) treated with systemic therapy, including anti-HER2 therapy, hormonal therapy, or cytotoxic therapies based on their molecular features.
Conclusions
This study highlights the unique molecular and biological features of metastatic EMPD, emphasizing the need for tailored treatment approaches. This information should be used to guide future clinical strategies for metastatic EMPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama 589-8511, Japan.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, United States.
- Genome Medical Center, Kindai University Hospital, Osaka-Sayama 589-8511, Japan.
- Kindai University Hospital Global Research Alliance Center, Osaka-Sayama 589-8511, Japan.
ORCID-Profile: Satomi Watanabe, Koji Haratani
Förderung
- JSPS KAKENHI
Zitieren
APA
Watanabe, S., Haratani, K., Nakayama, T., Takahama, T., Iwasa, T., Takeda, M., & Hayashi, H. (2025). Clinical and molecular landscape of metastatic extramammary Paget’s disease. The Oncologist, 30(9). https://doi.org/10.1093/oncolo/oyaf235
Vancouver
Watanabe S, Haratani K, Nakayama T, Takahama T, Iwasa T, Takeda M, et al. Clinical and molecular landscape of metastatic extramammary Paget’s disease. The Oncologist. 2025;30(9). doi:10.1093/oncolo/oyaf235
BibTeX
@article{Watanabe2025,
author = {Watanabe, Satomi and Haratani, Koji and Nakayama, Tomohiro and Takahama, Takayuki and Iwasa, Tsutomu and Takeda, Masayuki and Hayashi, Hidetoshi},
title = {Clinical and molecular landscape of metastatic extramammary Paget’s disease},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {9},
doi = {10.1093/oncolo/oyaf235}
}
EUVIMED